The Global Sterile Dosage Forms Industry is set to witness substantial growth, with a projected valuation of US$ 582.9 million in 2023, surging at an impressive Compound Annual Growth Rate (CAGR) of 6.7% throughout the forecast period. By 2033, the market is expected to reach a remarkable milestone of US$ 1.1 billion.
The sterile dosage forms market, a crucial segment within the pharmaceutical industry, specializes in the production and distribution of sterile pharmaceutical products. These products play a vital role in medical settings where maintaining a high level of sterility is paramount for patient safety and infection prevention.
Sterile dosage forms, devoid of living microorganisms, are designed to be administered through injection, infusion, or other parenteral methods. These forms find extensive application in critical care, cancer treatment, infectious diseases, and immunology. The product range includes sterile ointments, injectable solutions, suspensions, emulsions, and lyophilized powders.
Request a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17589
Numerous reasons have contributed to the enormous expansion of the worldwide sterile dosage form market. The rising incidence of chronic illnesses, which necessitate long-term management and frequently involve injectable drugs, is one of the main contributors. The need for sterile dosage forms for intraoperative and postoperative care is also influenced by increased surgical operations, notably in fields like orthopedics, cardiology, and general surgery.
The market for sterile dosage forms has expanded due to technological developments in medication delivery systems such as prefilled syringes, vials, and infusion pumps. These developments improve the ease, precision, and safety of medicine administration, which encourages more people to use sterile dosage forms.
Global Sterile Dosage Forms Industry Key Takeaways:
- The sterile dosage form industry in the United States is predicted to reach US$ 299.8 million by 2033, increasing at a 6.2% CAGR.
- The sterile dosage form industry in the United Kingdom is estimated to reach a market value of US$ 59.8 million, expanding at a CAGR of 5.8% by 2033.
- During the forecast period, China’s sterile dosage form industry is expected to reach a market value of US$ 98.3 million, securing an 8.0% CAGR.
- The sterile dosage form industry in Japan is predicted to reach US$ 58.6 million by 2033, increasing at a 7.0% CAGR.
- South Korea’s sterile dosage form industry is predicted to achieve a market value of US$ 53.8 million, rising at a 7.7% CAGR during the forecast period.
- With a CAGR of 6.5% from 2023 to 2033, the parenteral drugs segment is expected to dominate the sterile dosage form industry.
- With a CAGR of 6.4% from 2023 to 2033, the aqueous form is expected to dominate the sterile dosage form industry.
Global Sterile Dosage Forms Industry Key Players:
- Adelphi Healthcare Packaging
- APG Europe
- Bormioli Pharma S.p.a.
- Corning Incorporated
- Dalton Pharma Services
- DWK Life Sciences GmbH
- Nipro Corporation
- Pacific Vial
- Piramal Glass
- Schott AG
Key Developments:
- In March 2023, Injectable medicine packaging solutions provider Bormioli Pharma, an international leader, revealed brisk expansion throughout its North American business in the year 2022, with revenues jumping by more than 40% year-over-year.
- In June 2023, To increase pharmaceutical manufacturing in India, SGD Pharma and Corning Incorporated recently established a partnership. As part of the collaboration, a fresh glass tube facility will be opened, and SGD Pharma will be able to use Corning’s Velocity® Vial technology platform.
Global Sterile Dosage Forms Industry Segmentation:
By Types:
- Ophthalmic preparations
- Otic preparations
- Nasal preparations
- Parenteral drugs
- Pulmonary or inhalational preparations
By Forms:
- Aqueous
- Non-aqueous Liquid
- Dry Powder
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- The Middle East & Africa
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
